Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TARBP2 | Q15633 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.38 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.38 |
| ▸ | USP1 | O94782 | 1/20 | 0.37 |
| ▸ | USP19 | O94966 | 1/20 | 0.37 |
| ▸ | WDR48 | Q8TAF3 | 1/20 | 0.37 |
| ▸ | PPARG | P37231 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | FAAH | O00519 | 1/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6703700 | 0.98 | TARBP2 (0.46) | TARBP2LMNAKDM4EALDH1A1PTPN1 | |
| SCHEMBL6705288 | 0.94 | TARBP2 (0.39) | TARBP2LMNAKDM4EALDH1A1PTPN1 | |
| SCHEMBL6986435 | 0.89 | TARBP2 (0.46) | TARBP2LMNAKDM4EALDH1A1PTPN1 | |
| SCHEMBL6988862 | 0.89 | PPARG (0.38) | TARBP2KDM4EPPARGSMN1; SMN2NPSR1 | |
| SCHEMBL27607598 | 0.86 | MAPT (0.36) | LMNAKDM4EALDH1A1PPARGSMN1; SMN2 | |
| SCHEMBL6990599 | 0.84 | FLT1 (0.38) | KDM4EALDH1A1MAPK1HSD17B10HPGD | |
| SCHEMBL6994309 | 0.83 | MAPT (0.41) | KDM4EALDH1A1PPARGSMN1; SMN2NPSR1 | |
| SCHEMBL27597552 | 0.82 | UTRN (0.37) | LMNAKDM4EALDH1A1SMN1; SMN2NPSR1 | |
| SCHEMBL21834496 | 0.80 | CYP1A2 (0.44) | LMNAALDH1A1SMN1; SMN2CYP1A2CYP3A4 | |
| SCHEMBL6993450 | 0.80 | FFAR2 (0.38) | FAAH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115872930-A | N-substituted 3,4-dihydroisoquinoline-1 (2H) -ketone derivative, composition thereof and application thereof in medicines | 贵州医科大学 | 2023-03-31 | — | — | CN | disclosed |
| EP-1313715-B1 | OXAZOLYL-ARYLOXYACETIC ACID DERIVATIVES AND THEIR USE AS PPAR AGONISTS | LILLY CO ELI (US) | 2007-08-01 | — | — | EP | disclosed |
| EP-1401434-B1 | MODULATORS OF PEROXISOME PROLIFERATOR ACTIVATED RECEPTORS (PPAR) | LILLY CO ELI (US) | 2006-11-15 | — | — | EP | disclosed |
| EP-1401434-A1 | MODULATORS OF PEROXISOME PROLIFERATOR ACTIVATED RECEPTORS (PPAR) | ELI LILLY AND COMPANY (US) | 2004-03-31 | — | — | EP | disclosed |
| US-20040024034-A1 | Oxazolyl-aryloxyacetic acid derivatives and their use as ppar agonists | BROOKS DAWN ALISA (US) | 2004-02-05 | — | — | US | disclosed |
| CN-1471517-A | OXAZOLYL-arylpropionic acid derivatives and their sue as PPAR agonists | — | 2004-01-28 | — | — | CN | disclosed |
| EP-1313716-A1 | OXAZOLYL-ARYLPROPIONIC ACID DERIVATIVES AND THEIR USE AS PPAR AGONISTS | ELI LILLY AND COMPANY (US) | 2003-05-28 | — | — | EP | disclosed |
| EP-1313715-A1 | OXAZOLYL-ARYLOXYACETIC ACID DERIVATIVES AND THEIR USE AS PPAR AGONISTS | ELI LILLY AND COMPANY (US) | 2003-05-28 | — | — | EP | disclosed |
| WO-2002100403-A1 | MODULATORS OF PEROXISOME PROLIFERATOR ACTIVATED RECEPTORS (PPAR) | ELI LILLY AND COMPANY (US) | 2002-12-19 | — | — | WO | disclosed |
| WO-2002018355-A1 | OXAZOLYL-ARYLOXYACETIC ACID DERIVATIVES AND THEIR USE AS PPAR AGONISTS | ELI LILLY AND COMPANY (US) | 2002-03-07 | — | — | WO | disclosed |
| WO-2002016331-A1 | OXAZOLYL-ARYLPROPIONIC ACID DERIVATIVES AND THEIR USE AS PPAR AGONISTS | ELI LILLY AND COMPANY (US) | 2002-02-28 | — | — | WO | disclosed |
| US-6204277-B1 | TREATING DIABETES | JAPAN TOBACCO INC. (JP) | 2001-03-20 | — | — | US | disclosed |
| CN-1233241-A | Propionic acid derivatives and uses thereof | JAPAN TOBACCO INC (JP) | 1999-10-27 | — | — | CN | disclosed |
| EP-0930299-A1 | PROPIONIC ACID DERIVATIVES AND APPLICATIONS THEREOF | Japan Tobacco Inc. (JP) | 1999-07-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040024034-A1 | Oxazolyl-aryloxyacetic acid derivatives and their use as ppar agonists | PPARA, PPARG, PPARD | TARBP2 4537/4885LMNA 3537/4885KDM4E 2795/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.